Moderna on Thursday announced that an experimental cancer vaccine it is developing with Merck — when combined with the latter’s Keytruda immunotherapy — has been proven in a clinical trial to cut the risk of recurrence or death from the "most serious form of skin cancer" by half after three years.
Related Keywords
New Jersey , United States , Massachusetts , Kenilworth , American , Christopher Occhicone Bloomberg , Artur Widak Nurphoto , Stephen Hoge , Reuters , Merck Research Laboratories , American Cancer Society , Merck Co , Getty Images , President Stephen Hoge , Health , Cancer , News ,
comparemela.com © 2020. All Rights Reserved.